Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party ; volume:59 ; number:2 ; day:2 ; month:12 ; year:2023 ; pages:247-254 ; date:2.2024
Bone marrow transplantation ; 59, Heft 2 (2.12.2023), 247-254, 2.2024
- Urheber
-
Duque Afonso, Jesús
Finke, Jürgen
Ngoya, Maud
Galimard, Jacques-Emmanuel
Craddock, Charles
Raj, Kavita
Bloor, Adrian
Nicholson, Emma
Eder, Matthias
Kim, Orchard
Valerius, Thomas
Snowden, John A.
Tholouli, Eleni
Crawley, Charles
Collin, Matthew
Wilson, Keith M. O.
Gadisseur, Alain
Protheroe, Rachel
Wagner-Drouet, Eva Maria
Savani, Bipin N.
Spyridonidis, Alexandros
Ciceri, Fabio
Nagler, Arnon
Mohty, Mohamad
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41409-023-02150-w
- URN
-
urn:nbn:de:101:1-2404160816018.742718209703
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Duque Afonso, Jesús
- Finke, Jürgen
- Ngoya, Maud
- Galimard, Jacques-Emmanuel
- Craddock, Charles
- Raj, Kavita
- Bloor, Adrian
- Nicholson, Emma
- Eder, Matthias
- Kim, Orchard
- Valerius, Thomas
- Snowden, John A.
- Tholouli, Eleni
- Crawley, Charles
- Collin, Matthew
- Wilson, Keith M. O.
- Gadisseur, Alain
- Protheroe, Rachel
- Wagner-Drouet, Eva Maria
- Savani, Bipin N.
- Spyridonidis, Alexandros
- Ciceri, Fabio
- Nagler, Arnon
- Mohty, Mohamad
- SpringerLink (Online service)
Ähnliche Objekte (12)
Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party
Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party
Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party
Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party
Untersuchung zur Pharmakokinetik von Melphalan
Allogeneic transplant for mixed phenotype acute leukemia (MPAL): characteristics and outcome in the ALWP-EBMT Database
Pharmakokinetik von Melphalan, Busulfan und Chlorambucil
Pharmakogenetik des Zytostatikums Melphalan : Charakterisierung des Membrantransportes
Intravitreal melphalan for persistent retinoblastoma vitreous seeds
Looking Ahead: Clinical Hematology International Turns One
Practicing Clinical Hematology During the COVID-19 Outbreak: A Challenge Like No Other
Clinical Hematology International: Why a New Journal in Hematology?
Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party
Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party
Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party
Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party
Untersuchung zur Pharmakokinetik von Melphalan
Allogeneic transplant for mixed phenotype acute leukemia (MPAL): characteristics and outcome in the ALWP-EBMT Database
Pharmakokinetik von Melphalan, Busulfan und Chlorambucil
Pharmakogenetik des Zytostatikums Melphalan : Charakterisierung des Membrantransportes
Intravitreal melphalan for persistent retinoblastoma vitreous seeds
Looking Ahead: Clinical Hematology International Turns One
Practicing Clinical Hematology During the COVID-19 Outbreak: A Challenge Like No Other
Clinical Hematology International: Why a New Journal in Hematology?
Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party
Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party
Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party
Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party
Untersuchung zur Pharmakokinetik von Melphalan
Allogeneic transplant for mixed phenotype acute leukemia (MPAL): characteristics and outcome in the ALWP-EBMT Database
Pharmakokinetik von Melphalan, Busulfan und Chlorambucil
Pharmakogenetik des Zytostatikums Melphalan : Charakterisierung des Membrantransportes
Intravitreal melphalan for persistent retinoblastoma vitreous seeds
Looking Ahead: Clinical Hematology International Turns One
Practicing Clinical Hematology During the COVID-19 Outbreak: A Challenge Like No Other